Tectonic Therapeutic Inc. Common Stock (TECX)

About TECX

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPC…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

60

Website

tectonictx.com/

Fundamentals

1-day range

$30.45$31.84

Market cap

$570.23M

P/E (trailing)

—

P/E (forward)

-6.62

EPS (trailing)

$-4.46

Dividend yield

—

Beta

1.31

Avg. volume

190.3K

Forecasts

9 analyst ratings

Tectonic Therapeutic Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• TECX

  Tectonic Therapeutic Inc. Common Stock

  $35.69

  ▼ 2.75%
  Market cap $570.23MP/E —
  $14.39$39.53
• RGNX

  REGENXBIO Inc. Common Stock

  $9.66

  ▲ 3.09%
  Market cap $583.15MP/E —
  $5.46$16.19
• ZURA

  Zura Bio Limited Class A Ordinary Shares

  $5.73

  ▼ 2.05%
  Market cap $542.44MP/E —
  $1.88$7.44
• PRME

  Prime Medicine Inc. Common Stock

  $3.62

  ▼ 0.69%
  Market cap $532.82MP/E —
  $2.67$6.94
• AUTL

  Autolus Therapeutics plc American Depositary Share

  $2.34

  ▼ 1.06%
  Market cap $532.31MP/E —
  $1.18$2.58
• DNA

  Ginkgo Bioworks Holdings Inc. Class A Common Stock

  $6.98

  ▼ 3.93%
  Market cap $528.15MP/E —
  $5.37$17.58
• PROK

  ProKidney Corp. Class A Ordinary Shares

  $1.84

  ▲ 1.10%
  Market cap $495.38MP/E —
  $1.3$3.48

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• HQH: After Biotech's Breakout Year, This Healthcare CEF Still Trades Below NAV; Buy
  SeekingAlpha · 8/7/2026
• Wells Fargo Maintains Overweight on Tectonic Therapeutic, Lowers Price Target to $93
  Benzinga · 8/7/2026
• Tectonic Therapeutic Q2 EPS $(1.18) Beats $(1.37) Estimate
  Benzinga · 8/6/2026

• Peter McNamara · August 12, 2026 · Option Exercise

  43 @ $14.71
• Peter McNamara · August 12, 2026 · Sale

  43 @ $35
• Peter McNamara · June 30, 2026 · Option Exercise

  172 @ $14.71
• Peter McNamara · June 30, 2026 · Sale

  172 @ $35
• Alise Reicin · June 20, 2026 · Tax Withholding

  924 @ $30.34
• Daniel Lochner · June 11, 2026 · Grant

  7.5K
• Tipirneni Praveen P. · June 9, 2026 · Grant

  10.2K
• Donenberg Phillip B. · June 9, 2026 · Grant

  10.2K
• Timothy A. Springer · June 9, 2026 · Grant

  10.2K
• Vitorovic Stefan · June 9, 2026 · Grant

  10.2K
• Jessica Caroline Chutter · June 8, 2026 · Grant

  20.4K
• Marcella K. Ruddy · May 4, 2026 · Sale

  1.1K @ $30
• Marcella K. Ruddy · April 1, 2026 · Sale

  1.0K @ $31.05
• Francois Nader · April 1, 2026 · Grant

  20.4K
• Marcella K. Ruddy · March 6, 2026 · Sale

  10.0K @ $30

Institutional Ownership

March 31, 2026

Total shares held

13.96M

Total value held

$416.45M

Institutional holders

108